Nilotinib Teva (Nilotinib)

Nilotinib works by selectively binding to the ATP‑binding site of the BCR‑ABL tyrosine kinase, blocking its activity. This inhibition stops downstream signaling that drives uncontrolled growth of leukemic cells, leading to reduced proliferation and increased apoptosis of the malignant clone.

The exact dose of nilotinib is determined by the prescribing physician based on the patient’s clinical condition, prior therapy, and laboratory parameters. Dosing instructions are provided on the prescription label and should be followed exactly as directed by the healthcare professional.

The safety of nilotinib in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and the drug should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding is not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor that offers higher potency and selectivity compared with first‑generation agents such as imatinib. Clinical studies have shown faster and deeper molecular responses, though the safety profile includes a higher risk of QT prolongation, requiring cardiac monitoring.

Nilotinib tablets should be stored at temperatures below 25 °C (77 °F). Keep them in the original blister pack, protect from moisture and direct light, and store out of reach of children.

Nilotinib is taken orally, usually as whole tablets swallowed with a moderate‑fat meal to improve absorption. Patients should follow the dosing schedule prescribed by their physician and avoid crushing or chewing the tablets.

The most serious adverse events include QT interval prolongation, which can lead to life‑threatening arrhythmias, severe hepatic toxicity, and pancreatitis. Regular ECG monitoring, liver function tests, and clinical assessment are essential to detect these risks early.

Nilotinib is contraindicated in patients with a known hypersensitivity to the drug or any of its excipients, and in individuals with a baseline prolonged QT interval. Caution is also advised for patients with significant hepatic impairment or uncontrolled cardiovascular disease.